IKZF2-degrader 5
IKZF2-degrader 5 is a highly efficient, highly selective, rapidly acting, and orally active IKZF2 molecular glue degrader. IKZF2-degrader 5 induces IKZF2 degradation via the Cullin-CRBN-dependent pathway. IKZF2-degrader 5 promotes the production of pro-inflammatory IL-2. IKZF2-degrader 5 attenuates the immunosuppressive function of regulatory T cells (Tregs). IKZF2-degrader 5 triggers rapid, significant, and sustained IKZF2 degradation in the spleen and thymus of mice. IKZF2-degrader 5 inhibits tumor growth. IKZF2-degrader 5 can be used for the research of B16F melanoma.
For research use only. We do not sell to patients.
- Formula: C33H35N7O3
- Molecular Weight:577.68
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
IC50 & Target
[1]|
IKZF2 |
IL-2 |
In Vitro
IKZF2-degrader 5 (compound 25) (48 h) induces potent IKZF2 degradation in IKZF2-HiBit engineered HEK293T cells, with a DC50 of 0.00178 μM and a maximum degradation rate of 93.2%[1].
IKZF2-degrader 5 (0.001-1 μM; 24 h) induces potent, dose-dependent degradation of endogenous IKZF2 in Jurkat T and MV-4-11 cells[1].
IKZF2-degrader 5 (0.001-1 μM; 24 h) induces dose-dependent reductions in MYC and HOXA9 protein levels in MV-4-11 acute myeloid leukemia cells[1].
IKZF2-degrader 5 (0.001-10 μM; 24 h) induces CRBN-dependent IKZF2 degradation in HEK293T cells, whereas its activity is completely ablated in CRBN-/- cells[1].
IKZF2-degrader 5 (0.001-10 μM; 6 h) induces potent, dose-dependent degradation of IKZF2 in primary human CD25+ regulatory T cells, with a DC50 of 6.19 nM and a maximum degradation rate of 89.9%[1].
IKZF2-degrader 5 (0.001-1 μM; 24 h) promotes IL-2 secretion in CD3/CD28-activated Jurkat T cells in a dose-dependent manner[1].
IKZF2-degrader 5 (0.001-1 μM) dose-dependently enhances IFN-γ production in in vitro induced exhausted CD4+ and CD8+ effector T cells[1].
IKZF2-degrader 5 (0.1 μM; 24 h) alters gene expression in Jurkat T cells and significantly activates the T cell receptor, TNF signaling pathway, and NF-κB signaling pathway[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:Jurkat T cells
-
Concentration:1, 10, 100, 1000 nM
-
Incubation Time:24 h
-
Result:Elicited dose-dependent IKZF2 degradation, with near-complete degradation achieved at 0.1 μM after 24 h.
Achieved a DC50 for IKZF2 degradation of 1.59 nM with a Dₘₐₓ of 92.2%.
Caused minimal degradation of IKZF1, IKZF3, SALL4, GSPT1, CK1α, or ZFP91.
Parmacokinetics
In Vivo
IKZF2-degrader 5 (10-30 mg/kg; p.o.; single administration) induces rapid, potent and sustained degradation of IKZF2 in the spleen and thymus of mice[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:humanized CRBNI391V C57BL/6 mice[1]
-
Dosage:30 mg/kg
-
Administration:p.o.; once daily; 24 days
-
Result:Achieved a tumor growth inhibition (TGI) rate of 77.30%, with a mean tumor volume of 550.7 mm3 (compared to vehicle control mean tumor volume of 1581.4 mm3).
Caused no significant body weight loss or systemic toxicity.
-
Animal Model:humanized CRBNI391V C57BL/6 mice[1]
-
Dosage:10 mg/kg; 30 mg/kg
-
Administration:p.o.; single dose
-
Result:Reduced IKZF2 levels to 32.2% of vehicle control in the spleen and 16.6% of vehicle control in the thymus at 3 h post-administration of 30 mg/kg.
Reduced IKZF2 levels to 36.0% of vehicle control in the spleen and 44.2% of vehicle control in the thymus at 6 h post-administration of 10 mg/kg.
Reduced IKZF2 levels to 23.7% of vehicle control in the spleen and 27.7% of vehicle control in the thymus at 6 h post-administration of 30 mg/kg.
Reduced IKZF2 levels to 26.5% of vehicle control in the spleen and 32.6% of vehicle control in the thymus at 12 h post-administration of 10 mg/kg.
Reduced IKZF2 levels to 16.7% of vehicle control in the spleen and 20.6% of vehicle control in the thymus at 12 h post-administration of 30 mg/kg.
Chemical Information
-
Molecular Weight 577.68
-
Formula C33H35N7O3
-
SMILES
O=C1N(C2CCC(NC2=O)=O)N(C)CC3=C1C=CC(NCC4=CC(CN5CCN(C6=CC=CC(C#N)=C6)CC5)=CC=C4)=C3
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Patient-Derived Xenograft (PDX)
Patient-derived xenograft (PDX) models are generated by engrafting primary human tumor tissue directly into immunodeficient mice, allowing in vivo propagation of patient tumor biology without initial in vitro adaptation. These models are used to preserve key histopathological and molecular characteristics of the original tumor and enable assessment of tumor growth dynamics and therapeutic response in a living organism. The biological readout is tumor engraftment and subsequent growth in the murine host, which reflects the ability of human tumor cells to survive, vascularize, and expand in an immunocompromised microenvironment.
-
Patient-Derived Orthotopic Xenograft (PDOX)
Patient-derived orthotopic xenograft (PDOX) modeling implants fresh patient tumor tissue or patient-derived tumor cells into the anatomically corresponding organ or tissue site of immunodeficient mice, usually by surgical orthotopic implantation, to preserve patient tumor histology, local microenvironmental context, invasion, metastatic behavior, and treatment-response features better than subcutaneous implantation. PDOX readouts include tumor engraftment, orthotopic tumor growth, local invasion, metastasis, recurrence after resection, histologic similarity to the donor tumor, biomarker retention, molecular concordance, survival, and response or resistance to therapy. PDOX models are used for preclinical drug testing and individualized therapy evaluation, but engraftment success varies by tumor type and specimen quality.
-
Research Protocol for Inflammation-related Diseases
The NLRP3 inflammasome is a cytosolic innate immune signaling platform that integrates priming signals and danger-signal activation to promote caspase-1 activation, maturation of IL-1β and IL-18, and gasdermin D-mediated pyroptotic cell death. The core experimental logic is to determine whether inflammatory disease phenotypes are driven by increased NLRP3 expression, ASC-containing inflammasome assembly, caspase-1 cleavage, GSDMD cleavage, and extracellular release of IL-1β/IL-18 rather than by nonspecific cell injury alone. The pathway is strongly linked to inflammation-related disease phenotypes because monosodium urate crystals activate NALP3/NLRP3 inflammasome signaling in gout-like crystal inflammation, cholesterol crystals activate NLRP3 inflammasomes in atherogenesis models, and DSS-induced intestinal inflammation has been reported to involve NLRP3 inflammasome activity. However, experimental colitis studies also show context-dependent protective effects of NLRP3 inflammasome co
-
Subcutaneous Cell-Line-Derived Xenograft
Subcutaneous cell-line-derived xenograft (CDX) models are established by implanting cultured human cancer cell lines into immunodeficient mice, where the injected cells form localized tumors that can be monitored in vivo as a measure of tumorigenic potential, growth kinetics, and treatment response. These models are widely used in oncology research because they allow reproducible tumor formation and enable comparative assessment of tumor growth between different cell lines or genetic manipulations in a controlled in vivo microenvironment. Subcutaneous implantation of cancer cells in immunodeficient mice is a standard approach for evaluating tumor growth behavior and therapeutic response across multiple cancer types, including prostate, esophageal, pancreatic, and colon cancer models.
-
Orthotopic Cell-Line Xenograft
Orthotopic cell-line xenograft models involve implantation of human cancer cell lines into the anatomically corresponding organ of immunodeficient mice to reproduce tumor growth within a native microenvironment, enabling more clinically relevant tumor behavior compared with subcutaneous models. These models are widely used because orthotopic placement better recapitulates tumor progression, including invasion and metastatic spread, which are often underrepresented in heterotopic implantation systems. Compared with conventional xenografts, orthotopic implantation is described as more technically complex but provides improved simulation of tumor-microenvironment interactions and metastatic behavior, making it particularly valuable for translational oncology research. Surgical orthotopic implantation approaches have been emphasized as enabling faithful reproduction of clinical cancer features, including metastasis and disease progression patterns that align with the tumor’s organ of origi
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)